BACKGROUND: For patients with mild chronic hepatitis C the cost effectiveness of antiviral therapy is unknown. AIMS: To assess whether antiviral therapy (either interferon alpha or peginterferon alpha combined with ribavirin) is cost effective at a mild stage compared with waiting and only treating those cases who progress to moderate disease. PATIENTS: Cases with mild chronic hepatitis C. METHODS: A cost effectiveness model which estimates long term costs and outcomes for patients with mild chronic hepatitis C. The model uses effectiveness and cost data from the UK mild hepatitis C randomised controlled trial, combined with estimates of disease progression and cost from observational studies. RESULTS: Antiviral treatment at a mild rather than a moderate stage improved outcomes measured by quality adjusted life years (QALYS) gained. The mean cost per QALY gained from antiviral treatment with interferon alpha-2b and ribavirin, compared with no treatment at a mild stage, was 4535 pounds sterling (7108 dollars) for patients with genotype non-1 and 25,188 pounds sterling (39,480 dollars) for patients with genotype 1. Providing peginterferon alpha-2b and ribavirin at a mild rather than a moderate stage was also associated with a gain in QALYS; the costs per QALY gained were 7821 pounds sterling (12,259 dollars) for patients with genotype non-1 and 28,409 pounds sterling (44,528 dollars) for patients with genotype 1. CONCLUSIONS: For patients with chronic hepatitis C, it is generally more cost effective to provide antiviral treatment at a mild rather than a moderate disease stage. For older patients (aged 65 years or over) with genotype 1, antiviral treatment at a mild stage is not cost effective.
BACKGROUND: For patients with mild chronic hepatitis C the cost effectiveness of antiviral therapy is unknown. AIMS: To assess whether antiviral therapy (either interferon alpha or peginterferon alpha combined with ribavirin) is cost effective at a mild stage compared with waiting and only treating those cases who progress to moderate disease. PATIENTS: Cases with mild chronic hepatitis C. METHODS: A cost effectiveness model which estimates long term costs and outcomes for patients with mild chronic hepatitis C. The model uses effectiveness and cost data from the UK mild hepatitis C randomised controlled trial, combined with estimates of disease progression and cost from observational studies. RESULTS: Antiviral treatment at a mild rather than a moderate stage improved outcomes measured by quality adjusted life years (QALYS) gained. The mean cost per QALY gained from antiviral treatment with interferon alpha-2b and ribavirin, compared with no treatment at a mild stage, was 4535 pounds sterling (7108 dollars) for patients with genotype non-1 and 25,188 pounds sterling (39,480 dollars) for patients with genotype 1. Providing peginterferon alpha-2b and ribavirin at a mild rather than a moderate stage was also associated with a gain in QALYS; the costs per QALY gained were 7821 pounds sterling (12,259 dollars) for patients with genotype non-1 and 28,409 pounds sterling (44,528 dollars) for patients with genotype 1. CONCLUSIONS: For patients with chronic hepatitis C, it is generally more cost effective to provide antiviral treatment at a mild rather than a moderate disease stage. For older patients (aged 65 years or over) with genotype 1, antiviral treatment at a mild stage is not cost effective.
Authors: U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong Journal: Gut Date: 2003-03 Impact factor: 23.059
Authors: G Fattovich; G Giustina; F Degos; F Tremolada; G Diodati; P Almasio; F Nevens; A Solinas; D Mura; J T Brouwer; H Thomas; C Njapoum; C Casarin; P Bonetti; P Fuschi; J Basho; A Tocco; A Bhalla; R Galassini; F Noventa; S W Schalm; G Realdi Journal: Gastroenterology Date: 1997-02 Impact factor: 22.682
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay Journal: J Virol Date: 2014-04-23 Impact factor: 5.103
Authors: David B Rein; Bryce D Smith; John S Wittenborn; Sarah B Lesesne; Laura D Wagner; Douglas W Roblin; Nita Patel; John W Ward; Cindy M Weinbaum Journal: Ann Intern Med Date: 2011-11-04 Impact factor: 25.391
Authors: Elizabeth Hancock; Zoe Ward; Rachel Ayres; Jane Neale; Deborah Hussey; Joanna May Kesten; Matthew Hickman; Peter Vickerman Journal: Addiction Date: 2019-11-19 Impact factor: 6.526
Authors: Carmen E Gómez; Beatriz Perdiguero; María Victoria Cepeda; Lidia Mingorance; Juan García-Arriaza; Andrea Vandermeeren; Carlos Óscar S Sorzano; Mariano Esteban Journal: J Virol Date: 2013-04-17 Impact factor: 5.103